Randomized controlled trialHuman

End-organ protective effect of serelaxin in patients hospitalized for heart failure: Results of the biomarker substudy of Relaxin in Acute Heart Failure-2 (RELAX-AHF-2)

European journal of heart failure, 2025 Jul. Voors AA, Metra M, Postmus D and 10 others.

Study type

Randomized controlled trial

Subjects

Human participants (PubMed MeSH: Humans)

Journal

European journal of heart failure

Published

2025 Jul

PubMed

PMID 39663924 ↗

DOI

10.1002/ejhf.3551 ↗

Full text

Free on PubMed Central (PMC12370583) ↗

Where PepCue cites this

This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.

B7-33 →

Indexed under

MeSH terms assigned by the National Library of Medicine.

HumansRelaxinHeart FailureMaleFemaleAgedBiomarkersRecombinant ProteinsHospitalizationPeptide FragmentsNatriuretic Peptide, BrainTroponin T

Other papers on B7-33

Review · 2024

Relaxin agonists under preclinical and early clinical investigation for the treatment of heart failure

Journal article · 2023

The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy

Journal article · 2016

A single-chain derivative of the relaxin hormone is a functionally selective agonist of the G protein-coupled receptor, RXFP1

PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.

Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page